AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00680069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
Study NCT03185182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioflupane I123
Description: 185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution.
Study NCT01353846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observation natural cycle
Description: The patients natural reproductive cycle will be observed and compared to the second arm.
Study NCT01353846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist GnRH; estradiol Valerate; progesterone
Description: Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
Study NCT06133218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel Film
Description: A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
Study NCT01660022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg OZ439 single oral dose
Description: 100mg OZ439 oral suspension single dose
Study NCT01465698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study
Study NCT01465698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
Study NCT01465698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and counseling
Description: Participants take part in both exercise and counseling as described in the separate interventions.
Study NCT01465698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants in the control group take part only in measurements of NURSE-RCT.
Study NCT05337813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz Medical Extracoporeeal Shock Wave Therapy System
Description: A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
Study NCT06503861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Is Medicine intervention
Description: The intervention provides regular meal kits as well as cooking and nutritional education.
Study NCT01228513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK245186
Description: Daily topical application
Study NCT01660022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01660022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg OZ439 single oral dose
Description: 300mg OZ439 oral suspension single dose
Study NCT01660022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160mg Piperaquine single oral dose
Description: 160 mg Piperaquine tablet
Study NCT01660022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480mg Piperaquine single oral dose
Description: 480 mg Piperaquine tablet
Study NCT01660022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1440mg Piperaquine single oral dose
Description: 1440 mg Piperaquine tablet
Study NCT01660022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg OZ439 single oral dose
Description: 800mg OZ439 oral suspension single dose
Study NCT05659524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal saline irrigation
Description: The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~* Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~* Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
Study NCT04464109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evisceration with orbital implantation
Description: Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.
Study NCT00612677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days
Study NCT00612677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days
Study NCT01473147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide 5 microgram bid sc.
Study NCT01473147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 2 u bid sc.
Study NCT01118026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD
Description: doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV
Study NCT01118026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP
Description: bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14
Study NCT01118026 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02428582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covered stent (Atrium Type V12)
Description: An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
Study NCT01228513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle without active ingredient)
Description: Daily topical application
Study NCT02428582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare stent (Brand Cordis Type Palmaz Blue)
Description: An endovascular treatment that consists of inserting a stent into the stenosed vessels.
Study NCT01328912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning stimulus
Description: The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
Study NCT01328912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
Study NCT01272089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Description: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
Study NCT04285762 — intervention group
Intervention type: OTHER
Intervention: LVEEA
Description: lymphaticovenous end-to-end
Study NCT04285762 — intervention group
Intervention type: OTHER
Intervention: LVESA
Description: lymphaticovenous end-to-side
Study NCT04285762 — intervention group
Intervention type: OTHER
Intervention: LVSEA
Description: lymphaticovenous side-to-end
Study NCT02920359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEUPRORELIN ACETATE
Study NCT00414206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecamylamine
Study NCT00414206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00919763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD2027 Ointment 3 mcg/g, twice daily
Description: Topical Ointment
Study NCT00919763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ointment, twice daily
Description: Topical Ointment
Study NCT02008253 — intervention group
Intervention type: PROCEDURE
Intervention: INTRASTROMAL CORNEAL RING SEGMENT
Description: Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
Study NCT02351258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 70% Isopropyl alcohol embedded caps
Description: Protective cap on central lines
Study NCT02351258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: This involves the Best Practice Central Line Maintenance Care Bundle which includes;~1. Daily assessment whether central line is needed~2. Central line Site Care~3. Central line Hub/Cap/Tubing Care
Study NCT00430313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-Stimulation of Yongquan (K1) Acupoint
Description: Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
Study NCT02739035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg of IV dexamethasone immediately before MUA.
Study NCT02739035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 2 weeks per mouth of celecoxib (200 mg daily)
Study NCT01336283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
Study NCT01336283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
Study NCT01336283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
Study NCT03839277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff Vision
Description: Endocuff Vision is attached to the tip of colonoscope before intubation.
Study NCT03955939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.
Study NCT03955939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Administered according to label instructions.
Study NCT03955939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.
Study NCT02809820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Patients randomized to this group will receive carvedilol at the highest dose tolerated
Study NCT02809820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Patients randomized to this group will receive metoprolol at the highest dose tolerated
Study NCT03451435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
Study NCT04025606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural
Description: Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
Study NCT02008708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Livestock Microfinance
Description: Participants randomized to the microfinance group receive the pig loan.
Study NCT02008708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control Group
Description: Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
Study NCT04025606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
Study NCT03896828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed-macronutrient meal
Description: Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches.
Study NCT03143192 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Micropulse Laser
Description: Aflibercept injection with Micropulse laser.
Study NCT03143192 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser
Description: Aflibercept injection with Sham Laser
Study NCT01774994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope infusion for measurement of metabolism
Study NCT03405376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Description: Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
Study NCT00738361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
Study NCT05520606 — intervention group
Intervention type: PROCEDURE
Intervention: pancreatoduodenectomy
Description: Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
Study NCT00003330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study NCT02953678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT02953678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or methylprednisolone
Description: Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
Study NCT03081039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
Study NCT03081039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
Study NCT03081039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight.
Study NCT04633642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Description: Every week during a six-week treatment period
Study NCT04633642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical group
Description: Every week during a six-week treatment period
Study NCT03442010 — intervention group
Intervention type: OTHER
Intervention: Detection of adverse drug events
Description: Detection of adverse drug events
Study NCT02356211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial Falls Assessment
Description: The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
Study NCT02346682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
Study NCT01901848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
Study NCT01901848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
Study NCT01901848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
Study NCT01901848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy (NRT)
Description: NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
Study NCT01901848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy (NRT)
Description: NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
Study NCT01901848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care for Smoking Cessation (ICSC)
Description: ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
Study NCT01901848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Care for Smoking Cessation (ICSC)
Description: ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
Study NCT04267250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: 60 mg by mouth (PO) once daily (QD).
Study NCT04267250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonorgestrel (LN)
Description: Oral tablet containing 30 mcg EE and 150 mcg LN.
Study NCT01901848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smokefreeVET
Description: SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.